Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 13/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11900553 | 0.86 | PDE4B (0.54) | PDE4BPDE4DTP53MEN1KMT2A | |
| SCHEMBL11902100 | 0.86 | PDE4B (0.50) | PDE4BPDE4DMEN1KMT2AS1PR1 | |
| SCHEMBL11901109 | 0.84 | PDE4B (0.47) | PDE4BPDE4DTP53MEN1MAPT | |
| SCHEMBL11900976 | 0.84 | PDE4B (0.47) | PDE4BPDE4DTP53MEN1MAPT | |
| SCHEMBL2508259 | 0.80 | PDE4B (0.51) | PDE4BPDE4DMEN1KMT2A | |
| SCHEMBL13506512 | 0.80 | PDE4B (0.51) | PDE4BPDE4DMEN1KMT2A | |
| SCHEMBL12472870 | 0.78 | PDE4B (0.51) | PDE4BPDE4DTP53MEN1CYP1A2 | |
| SCHEMBL30777159 | 0.78 | PDE10A (0.43) | PDE4BPDE4DS1PR1 | |
| SCHEMBL27168448 | 0.78 | PDE10A (0.43) | PDE4BPDE4DS1PR1 | |
| SCHEMBL13506460 | 0.77 | PDE2A (0.43) | PDE4BPDE4DTP53CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| CN-103476767-A | Heterocyclic compounds as PI3 kinase inhibitors | HOFFMANN LA ROCHE | 2013-12-25 | — | — | CN | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, AKT3 | PDE4B 1402/4885PDE4D 1775/4885TP53 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.